Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Transgene Biotek Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Transgene Biotek Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Transgene Biotek Ltd
BSE:526139
Total Receivables
â‚ą8.4B
CAGR 3-Years
4 542%
CAGR 5-Years
888%
CAGR 10-Years
N/A
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Total Receivables
â‚ą100.3m
CAGR 3-Years
-15%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Total Receivables
â‚ą53m
CAGR 3-Years
23%
CAGR 5-Years
6%
CAGR 10-Years
20%
Hester Biosciences Ltd
NSE:HESTERBIO
Total Receivables
â‚ą999.1m
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Biocon Ltd
NSE:BIOCON
Total Receivables
â‚ą72.6B
CAGR 3-Years
83%
CAGR 5-Years
46%
CAGR 10-Years
25%
Panacea Biotec Ltd
NSE:PANACEABIO
Total Receivables
â‚ą670.8m
CAGR 3-Years
-19%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
No Stocks Found

Transgene Biotek Ltd
Glance View

Market Cap
525.8m INR
Industry
Biotechnology

Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

TRABI Intrinsic Value
0.29 INR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Transgene Biotek Ltd's Total Receivables?
Total Receivables
8.4B INR

Based on the financial report for Sep 30, 2024, Transgene Biotek Ltd's Total Receivables amounts to 8.4B INR.

What is Transgene Biotek Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
888%

Over the last year, the Total Receivables growth was 9 999 900%. The average annual Total Receivables growth rates for Transgene Biotek Ltd have been 4 542% over the past three years , 888% over the past five years .

Back to Top